· Next generation design enhancing the persistence of T cells in vivo
· High affinity/avidity/specificity against tumor specific antigen
· BRL03: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.
· Able to be cryopreserved to address long distance transportation issue
· Does not require high dose IL-2 infusion
· BST02: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.
· In-human data showing clinical efficacy
· Unique target/FIC
· Enhanced safety profile
· BRG01: Ongoing Phase II clinical trials in China/U.S.
· BGT007: Dual CAR-T, IIT in progress
· ALLO-CEL: In-human by 2024
· Improved production cycle time of CAR-T/TCR-T product to 10-days.
· Manufactured in GMP facility in compliance to FDA and CDE requirements.
· Unique T cell signaling tweaking strategy and TME-specific promoter to broaden tumor cell coverage while ensuring safety.
· Library consisting of hundreds of motifs for T cell functional enhancement.
· Large tumor-specific TCR library for multiple high-frequency HLA haplotypes.
· Fast screening / optimization.
Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.
Collaboration targets multiple indications . exclusive collaboration in NPC.
13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government
Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.
Collaboration targets multiple indications . exclusive collaboration in NPC.
13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government
Dual site strategy with dual R&D and GMP Facilities to address Global needs
